Telmisartan to prevent recurrent stroke and cardiovascular eventsMedical University, Soudi Carolina, Charleston, United States.
Medical University, Soudi Carolina, Charleston, United States.
Stanford University, Medical Center, Palo Alto, CA, United States.
University of Nottingham, Nottingham, United Kingdom.
Ichilov Medical Center, Tel-Aviv, Israel.
National University Hospital, Singapore, Singapore.
Chang Gung Memorial Hospital, Tapei, Taiwan.
Hospitais da Universidade de Coimbra, Coimbra, Portugal.
Sahlgrenska University Hospital, Östra, Göteborg, Sweden.
University Medical Center Groningen, Groningen, Netherlands.
National Stroke Research Institute, Austin Health, University of Melbourne, Heidelberg West, Australia.
Neurological Center for Treatment and Research, Buenos Aires, Argentina.
University of Illinois, Chicago, United States.
Boehringer Ingelheim, Ridgefield, CT, United States.
Helsinki University, Central Hospital, Helsinki, Finland.
Huashan Hospital, Shanghai, China.
St. Johns's Medical College, Bangalore, India.
Clinical Trials Methodology Group, McMaster University, Hamilton, ON, Canada.
Russian State Medical University, Moscow, Russian Federation.
University of British Columbia, Vancouver, Canada.
University La Sapienza, Rome, Italy.
Boehringer Ingelheim, Ridgefield, CT, United States.
Boehringer Ingelheim, Ridgefield, CT, United States.
Boehringer Ingelheim, Ridgefield, CT, United States.
Seoul National University Hospital, Seoul, South Korea.
Show others and affiliations
2008 (English)In: New England Journal of Medicine, ISSN 0028-4793, E-ISSN 1533-4406, Vol. 359, no 12, p. 1225-1237Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.
METHODS: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes.
RESULTS: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10).
CONCLUSIONS: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)
Place, publisher, year, edition, pages
Massachusetts medical society , 2008. Vol. 359, no 12, p. 1225-1237
National Category
Medical and Health Sciences Neurosciences
Identifiers
URN: urn:nbn:se:oru:diva-81161DOI: 10.1056/NEJMoa0804593ISI: 000259259900006PubMedID: 18753639Scopus ID: 2-s2.0-5224911677OAI: oai:DiVA.org:oru-81161DiVA, id: diva2:1424020
2020-04-162020-04-162024-01-02Bibliographically approved